Actively Recruiting
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Led by Kumquat Biosciences Inc. · Updated on 2026-02-06
100
Participants Needed
35
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
CONDITIONS
Official Title
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older with advanced solid tumor cancer
- Histologically confirmed solid tumor with mutations in EGFR, RAS, PTPN11, SOS1, or NF1
- NSCLC with activating EGFR mutation and progression on osimertinib (for certain study arms)
- NSCLC with exon 20 insertion EGFR mutation (for specific cohort)
- Disease that is unresectable or metastatic
- No available treatments with curative intent
- Adequate organ function
- Measurable disease according to RECIST 1.1 criteria
You will not qualify if you...
- Prior treatment with drugs having a similar mechanism as KQB198
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal issues that affect drug absorption or swallowing
- History of interstitial lung disease
- Cardiac abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 35 locations
1
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States, 80218
Actively Recruiting
2
Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona -
Orlando, Florida, United States, 32827
Actively Recruiting
3
Florida Cancer Specialists - Sarasota
Sarasota, Florida, United States, 34232
Actively Recruiting
4
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
5
David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center
Long Island City, New York, United States, 11101
Actively Recruiting
6
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio, United States, 45219
Actively Recruiting
7
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
8
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Withdrawn
9
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
10
New Experimental Therapeutics of Virginia - NEXT Oncology
Fairfax, Virginia, United States, 22031
Actively Recruiting
11
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France, 13009
Actively Recruiting
12
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, Loire-Atlantique, France, 44800
Actively Recruiting
13
CHU Bordeaux - Hopital Saint-Andre
Bordeaux, Nouvelle-Aquitane, France, 33000
Actively Recruiting
14
IUCT-Oncopole
Toulouse, Occitaine, France, 31059
Actively Recruiting
15
CHU de Nantes - Hopital Nord Laennec
Nantes, Pays de la Loire Region, France, 44000
Actively Recruiting
16
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Lazio, Italy, 00168
Actively Recruiting
17
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy, 80131
Actively Recruiting
18
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea, 10408
Withdrawn
19
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea, 58128
Withdrawn
20
Severance Hospital, Yonsei University Health System
Seoul, South Korea, 03722
Withdrawn
21
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea, 06591
Withdrawn
22
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Catalonia, Spain, 08028
Actively Recruiting
23
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, Spain, 08035
Actively Recruiting
24
New Experimental Therapeutics (NEXT) Oncology Barcelona
Barcelona, Spain, 08023
Actively Recruiting
25
South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos
Barcelona, Spain, 08023
Actively Recruiting
26
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Actively Recruiting
27
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain, 28040
Actively Recruiting
28
New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid
Madrid, Spain, 28223
Actively Recruiting
29
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
Actively Recruiting
30
Hospital Quirónsalud Málaga
Málaga, Spain, 29004
Actively Recruiting
31
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain, 31008
Actively Recruiting
32
Chi-Mei Hospital - Liouying Branch
Liuying, Tainan City, Taiwan, 73657
Withdrawn
33
National Taiwan University Hospital
Taipei, Taipei City, Taiwan, 100225
Withdrawn
34
Taichung Veterans General Hospital
Taichung, Taiwan, 40705
Withdrawn
35
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Withdrawn
Research Team
K
Kumquat Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here